Havana, March 2.- Bruno Rodríguez Parrilla, Minister of Foreign Affairs of Cuba, highlighted today the maximum scientific rigor with which the country's vaccine candidates against Covid-19 are developed.
In his Twitter account, the chancellor signified the guarantee of efficacy and safety in the clinical trials of Soberana 02 and Abdala, which this month begin phase III.
Likewise, he indicated that in order to guarantee complete protection, both drugs may be used in combination, since there are technological capacities installed in Cuba for this.
“#Cuba develops vaccine candidates against # COVID19 with the utmost scientific rigor as a guarantee of efficacy and safety. The technological capabilities installed will allow them to be used in combination to guarantee complete protection,” wrote Rodríguez Parrilla in the aforementioned social network.
The president of the Group of Biotechnology and Pharmaceutical Industries of Cuba ( BioCubaFarma ), Eduardo Martínez Díaz, recently reported that bothCandidates have caused the induction of a powerful immune response against the SARS-CoV-2 virus, which causes Covid-19.
He assured that as part of the phase II clinical trials, thousands of doses of the candidates Soberana 02 and Abdala have been applied in the country, and they have proven to be safe, with mild adverse events.
The drugs are produced on an industrial scale in the laboratories of the Center for Biopreparations and in the Aica Laboratories.
The general director of the Center for Molecular Immunology (CIM), Eduardo Ojito Magaz, announced that the first 340 thousand doses of Soberana 02 are released to begin its Phase III clinical trial, once approved by the Center for State Control of Medicines, Equipment and Medical Devices (CECMED).
For its part, the Finlay Vaccine Institute (IFV), the center in charge of Soberana02, announced yesterday that after its approval and publication in the registry of clinical trials, phase III will reach eight municipalities in Havana and will include 44,010 people. (Text and photo: ACN)